Pharmacist and doctor teamwork to help rheumatoid arthritis patients take medicines
Tests pharmacist and doctor teamwork to help adults with rheumatoid arthritis take their medicines.
Plain-language title generated from the registry record
Registry title: RhEumatoid Arthritis MEDIcation Adherence
Key facts
- Where
- Lyon and Pierre-Bénite, FranceSee the 2 sites
Where in France
- Service de rhumatologie et pathologie osseuse - Hôpital Edouard HerriotLyon, FranceTaking people
- Service de rhumatologie, Centre Hospitalier Lyon Sud, Groupement Hospitalier Sud, Hospices Civils de LyonPierre-Bénite, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT05413759
- Record updated
- 2 October 2025
- Original description
Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients.Read full original descriptionShow less
Collaborative Pharmaceutical Care Initiated in Hospital and Continued in Primary Care to Improve Medication Adherence of Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients.
Main objective:
To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration.
Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)).
METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.
Inclusion: Patient with diagnosed rheumatoid arthritis (RA),; Patient, male or female, aged 18 or over,; Patient hospitalized or coming for a consultation in a rheumatology department, and returned home at hospital discharge; Patient having DMARDs for RA (continuation or initiation) comprising at least methotrexate and/or a tsDMARD (targeted synthetic DMARD, JAK inhibitor) and/or subcutaneous bDMARD (biologic DMARD),; Autonomous patient in the management of his drug treatment,; Patient understanding and speaking French,; Patient affiliated to the French general national health insurance or similar,; Patient having given his free, informed and signed consent.
Exclusion: Patient whose management of his drug treatment at home is carried out exclusively by a carer,; Patient with obvious significant cognitive or psychiatric disorders incompatible with the study (according to the judgment of the investigator),; Patient whose usual pharmacy already has or has had a patient included in the INTERVENTION group in the study,; Patient whose regular pharmacy is currently treating another patient; Patient participating in another research that may interfere (investigator's judgement) with the results of the present study,; Adult patient protected under the terms of the law (Public Health Code),; Patient not fit to carry out the follow-up, according to the judgment of the investigator,; Pregnant or breastfeeding women.